Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
Autolus Therapeutics plc (Nasdaq: AUTL) has appointed Cardinal Health (NYSE: CAH) to facilitate the U.S. commercialization of its CAR T-cell therapies. This partnership includes a depot model for improved delivery efficiency, allowing the product to be positioned closer to treatment sites while awaiting final release. Cardinal Health will also assist with order-to-cash operations. Autolus is preparing to file a Biologics License Application (BLA) for its investigational therapy, obe-cel, by the end of 2023, with key data from the pivotal FELIX study to be presented at upcoming conferences in June. This effort aims to enhance patient access to innovative cancer therapies.
- Collaboration with Cardinal Health to enhance U.S. commercialization efforts.
- Depot model expected to reduce delivery times for CAR T-cell therapies.
- Planned BLA filing for obe-cel by the end of 2023, indicating progress in development.
- Presentation of pivotal FELIX study data at ASCO and EHA in June, potentially boosting investor confidence.
- None.
- Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapies
- Innovative Depot Model intended to reduce delivery time by allowing for transit while product release is finalized
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has selected Cardinal Health Inc. (NYSE: CAH) to support the launch and commercialization of its CAR T-cell therapies in the United States, subject to FDA approval.
Under the proposed agreement, Cardinal Health 3PL Services will establish essential capabilities for Autolus to commercialize a CAR T-cell therapy in the U.S., including a depot model that allows Autolus to maintain custody and physically position product closer to treatment sites during finalization of product release, with the goal of shortening vein-to-delivery times. In addition, Cardinal Health will help provide seamless order-to-cash capabilities.
“We are delighted to have selected Cardinal Health, an established leader in providing core services needed to commercialize CAR T-cell therapy, in the U.S.,” said Christopher Vann, SVP, Chief Operating Officer of Autolus. “This selection is an important milestone in the preparation for the commercialization of obe-cel. We look forward to presenting the primary data from the FELIX study at ASCO and EHA in June and are planning to file for a BLA with the FDA by the end of 2023.”
“We are very excited to partner with Autolus to provide order to cash management and our unique depot model to store their obe-cel,” said Joel Wayment, Vice President, Cardinal Health 3PL Services. “This collaboration will accelerate speed to market, ensuring that patients have more timely access to therapy.”
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 years in business, operations in more than 30 countries and approximately 46,500 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
About obe-cel (AUTO1)
Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus’ academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL. Autolus has progressed obe-cel to the FELIX trial, a pivotal trial for adult ALL.
About obe-cel FELIX clinical trial
Autolus’ Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the expected benefits of the Company’s arrangement with Cardinal Health; the continued development of Autolus’ obe-cel program, including the timing and content of clinical results obtained with obe-cel, and the presentation of such results; the planned submission of a Biologics License Application for obe-cel by the end of 2023; and the sufficiency of the Company’s cash resources and its anticipated cash runway into 2025. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus and Cardinal Health are unable agree on a definitive agreement, or that the arrangement described in such an agreement does not produce the desired results; Autolus’ preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing, and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 7, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
Alexandra Deschner
+32-490-58-35-23
a.deschner@autolus.com
FAQ
What is the significance of Autolus' partnership with Cardinal Health?
What is obe-cel and its relevance to Autolus?
When is Autolus planning to file for the BLA of obe-cel?
What clinical trial is associated with obe-cel?
When will Autolus present data from the FELIX study?
